Editorial CommentTranscatheter ablation is an effective approach for treating atrial fibrillation (AF) refractory to antiarrhythmic drugs. The main objective of AF ablation is the maintenance of sinus rhythm with a consequent reduction of AF-related symptoms and thromboembolic events.Within the complications worldwide described following transcathter AF ablation procedures, however, ischemic embolic accidents are the most frequent. In fact, symptomatic thromboembolic events have been reported ranging from 0.5% to 1%. 1 In addition, the use of postablation cerebral magnetic resonance imaging (MRI) 2,3 has proven that an AF ablation procedure may also cause silent cerebral ischemias (SCI) in up to 40-50% of the cases. 4,5 Given the evidence that SCI relate to an increased incidence of strokes, impaired cognitive function, and dementia, they cannot be considered riskless. 6 Physicians performing AF ablation, aiming at controlling symptoms and reducing thromboembolic events should therefore not, in first line, cause them. Several factors that may also coexist during an AF ablation procedure are known to cause SCI (Table 1). The major mechanisms involved include conventional clotting, thermal thrombus formation (charring), and air/gas embolisms.Introduction of any foreign body into the blood pool stimulates clot formation. This mechanism should however be effectively prevented by heparin bolus administration aiming at high activating clotting time (ACT > 300 seconds) and continued oral anticoagulation. Despite these presumptions, to date, contradictory results have been reported. In a study by our group, within 232 consecutive patients with paroxysmal or persistent AF undergoing radiofrequency transcatheter ablation, 33 (14%) reported new SCI at the postprocedural cerebral MRI. Within these, the incidence of SCI was 9% in patients heparinized to an ACT > 250 seconds while nearly double (17%) in those maintaining lower values. 3 In addition to ACT, intraprocedural electric or pharmacological cardioversion to sinus rhythm correlated with an increased incidence of SCI (P = 0.009). Furthermore, preliminary results of an ongoing multicenter study 7 performed, to date, on 51 patients undergoing transcatheter AF ablation under therapeutic oral anticoagulation in addition to a 10,000 U intravenous heparin bolus before transseptal punc-